Jason Kenealey

Dr. Jason Kenealey


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2017 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
JHJordan Hastings
Jordan Hastings
JKJason Kenealey
Jason Kenealey
Avenanthramides (AVN) are a relatively unstudied family of phytochemicals that could be novel chemotherapeutics. These compounds, found in oats, are non-toxic to healthy cells and have been shown to reduce viability of human colon and liver cancers in vitro. However, these studies do not elucidate a molecular mechanism for individual AVN. In this study we aim to see the effects of AVN on MDA-MB-231 breast cancer cells. An MTT assay was used to determine cell viability. Staining and analysis with a flow cytometer was used to identify cell cycle progression and apoptosis. FloJo software was used to analyze the cytometric data. In all experiments, statistical significance was determined by a two-tailed t test. This study demonstrates that AVN-A, B, and C individually reduce viability in the MDA-MB-231 breast cancer cell line. AVN-C has the most potent decrease in tumor cell viability, decreasing viable cells to below 25% at 400 µM when compared to control after 96 h. We demonstrate that treatment with AVN-C causes DNA fragmentation and accumulation of over 90% of cells into a sub G1 cell cycle population. Further, we conclude that AVN-C treated cells activate apoptosis because 97% of treated cells stain positive for annexin V while 91% have caspase-3/7 activity, a late marker of apoptosis. Breast cancer cells treated with AVN-C have a decrease in cell viability, an increase in the sub G1 population, and stain positive for both annexin V and caspase activity, indicating that AVN-C induces apoptosis in breast cancer cells. These compounds may be able to act as chemotherapeutics as demonstrated through future in vivo studies.

4 January 2024 in Food Chemistry
Verified
Journal Article
Closed access
CJCharity C. Jennings
Charity C. Jennings
MFMcCall Freidenberger
McCall Freidenberger
SCShawn A. Christensen
Shawn A. Christensen
JCJoy Conlin
Joy Conlin
OFOlivia Freidenberger
Olivia Freidenberger
JKJason Kenealey
Jason Kenealey

30 October 2014 in Molecules
Verified
Journal Article
Open access
PDF file
MKMozhgan Rezaei Kanavi
Mozhgan Rezaei Kanavi
SDSoesiawati Darjatmoko
Soesiawati Darjatmoko
SWShoujian Wang
Shoujian Wang
AAAmir A. Azari
Amir A. Azari
MFMitra Farnoodian
Mitra Farnoodian
APArthur Polans
Arthur Polans
The objective of this study was to determine whether resveratrol or a defined, reconstituted grape powder can attenuate the formation of new blood vessels in a mouse model of choroidal neovascularization (CNV). To accomplish this objective, C57BL/6J mice were randomized into control or treatment groups which received either resveratrol or grape powder by daily oral gavage, resveratrol or grape powder delivered ad libitum through the drinking water, or resveratrol by slow release via implanted osmotic pumps. A laser was used to rupture Bruch’s membrane to induce CNV which was then detected in sclerochoroidal eyecups stained with antibodies against intercellular adhesion molecule-2. CNV area was measured using fluorescence microscopy and Image J software. Ad libitum delivery of both resveratrol and grape powder was shown to significantly reduce the extent of CNV by 68% and 57%, respectively. Parallel experiments conducted in vitro demonstrated that resveratrol activates p53 and inactivates Akt/protein kinase B in choroidal endothelial cells, contributing to its anti-proliferative and anti-migratory properties. In addition resveratrol was shown to inhibit the formation of endothelial cell networks, augmenting its overall anti-angiogenic effects. The non-toxic nature of resveratrol makes it an especially attractive candidate for the prevention and/or treatment of CNV.

1 May 2021 in Clinical Nutrition
Verified
Journal Article
Closed access
KPKatharine Parsons
Katharine Parsons
LBLindsay Brown
Lindsay Brown
HCHannah Clark
Hannah Clark
EAEliza Allen
Eliza Allen
EMElyse McCammon
Elyse McCammon
JKJason Kenealey
Jason Kenealey

1 November 2021 in Journal of Dairy Science
Verified
Journal Article
Closed access
MAMuriel M. Allen
Muriel M. Allen
OPOscar A. Pike
Oscar A. Pike
JKJason Kenealey
Jason Kenealey
MDMichael L. Dunn
Michael L. Dunn
Acid whey, a byproduct of Greek yogurt production, has little commercial value due to its low protein content and is also environmentally harmful when disposed of as waste. However, as a product of microbial fermentation, acid whey could be a rich source of beneficial metabolites associated with fermented foods. This study increases understanding of acid whey composition by providing a complete metabolomic profile of acid whey. Commercial and laboratory-made Greek yogurts, prepared with 3 different bacterial culture combinations, were evaluated. Samples of uncultured milk and cultured whey from each batch were analyzed. Ultra-high-performance liquid chromatography-tandem mass spectrometry metabolomics were used to separate and identify 477 metabolites. Compared with uncultured controls, acid whey from fermented yogurt showed decreases in some metabolites and increases in others, presumably due to the effects of microbial metabolism. Additional metabolites appeared in yogurt whey but not in the uncultured control. Therefore, the effect of microbial fermentation is complex, leading to increases or decreases in potentially bioactive bovine metabolites while generating new microbial compounds that may be beneficial. Metabolite production was significantly affected by combinations of culturing organisms and production location. Differences between laboratory-made and commercial samples could be caused by different starting ingredients, environmental factors, or both.

1 August 2018 in Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
RORichard Oblad
Richard Oblad
HDHayden Doughty
Hayden Doughty
JLJohn Lawson
John Lawson
MCMerrill Christensen
Merrill Christensen
JKJason Kenealey
Jason Kenealey
Combining chemotherapeutics to treat malignant tumors has been shown to be effective in preventing drug resistance, tumor recurrence, and reducing tumor size. We modeled combination drug therapy in PC-3 human prostate cancer cells using mixture design response surface methodology (MDRSM), a statistical technique designed to optimize compositions to achieve the most desirable result. Conventional chemotherapeutics (mitoxantrone, cabazitaxel, and docetaxel) and natural bioactive compounds (resveratrol, piperlongumine, and flavopiridol) were used in twelve different combinations containing three different drugs at varying concentrations. Cell viability and cell cycle data were collected and used to plot response surfaces in MDRSM that identified the most effective concentrations of each drug in combination. The use of MDRSM for defining combinations of chemotherapeutics is novel. MDRSM allows for extrapolation of data from three or more compounds in non-constant ratio combinations, unlike the Chou-Talalay method. MDRSM combinations were compared with combination index data from the Chou-Talalay method and were found to coincide. We propose MDRSM as an effective tool in devising combination treatments that can improve treatment effectiveness, and increase treatment personalization because MDRSM measures effectiveness rather than synergism, potentiation or antagonism.